- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Study: OTC ibuprofen as effective as Rx in treating post-operative pain after having tonsils removed
- Prestige Brands solution to pediatric overdosing — unique squeezable, single-dose APAP packet
- Homeopathy, returning brands shape pain relief
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
RARITAN, N.J. — The Food and Drug Administration has approved a supplemental new drug application for an opioid analgesic to treat diabetes-related pain.
Johnson & Johnson subsidiary Janssen Pharmaceuticals said Nucynta (tapentadol) extended-release tablets has been approved for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Nucynta ER currently is the only FDA-approved opioid for neuropathic pain associated with DPN, Janssen said.
"The approval of Nucynta ER for DPN pain represents the ongoing commitment of Janssen to bring new and innovative products to patients and physicians for the management of pain," Janssen Pharmaceuticals VP medical affairs Paul Chang said. "It is exciting that our in-depth experience in pain management allows us to continue to provide patients with effective options to treat their pain."